In older patients with inflammatory bowel disease, tumor necrosis factor alpha antagonist therapy and vedolizumab were found to be comparable with regard to both safety and effectiveness.
Patients with Crohn disease were enrolled in a comparative cohort study that analyzed the outcomes of reference product infliximab vs biosimilar treatment.
Women with Crohn disease who use oral contraceptives for more than 1 year have an increased risk of surgery.
The biosimilar has also been approved for Crohn’s disease, ulcerative colitis, and ankylosing spondylitis.
Patients with Crohn disease who ate high-fiber foods were 40% less likely to have a disease flare.
A condition prone to recurrence, Crohn disease has a complicated presentation and pathophysiology, but multiple treatment options are available.
Entyvio can be used to treat ulcerative colitis and Crohn disease in adults who did not have success with other treatments.
People with airway diseases are more likely to have inflammatory bowel disease.
The FDA has approved vedolizumab for patients with inadequate response to conventional therapies.
Early monotherapy with such anti-TNF-alpha agents as infliximabor and adalimumab may produce better overall clinical and growth outcomes.
